In person ZoBio is pleased to attend the RSC-BMCS Fragment-Based Drug Discovery meeting in Cambridge this September. ZoBio will be represented by Johan Veerman | LinkedIn, Head of Chemistry, who will also present a poster entitled: Site-selective screening: Design, synthesis and application of stable S-adenosylmethionine-based probes for fragment screening against METTL3/14 We look forward to…
EUROMAR 2026
In person As in the previous years ZoBio attended the European Conference on Magnetic Resonance, which took place in Göteborg, Sweden. Stephan Theisgen presented a poster demonstrating how strategically integrating solution-state NMR into commercial drug discovery programs provides critical structural insights across the early preclinical pipeline. The poster highlighted how NMR complements biochemical assays, biophysical…
ZoBio Launches Comprehensive DEL Hit Discovery Service for Challenging Targets
LEIDEN, NL
ZoBio, a boutique problem-solving Contract Research Organization (CRO) specializing in early gene-to-lead discovery, today announced the launch of its comprehensive…
RICT 2026
Molecular glues are rapidly emerging as a transformative modality in drug discovery, enabling novel mechanisms to modulate protein function through stabilization of protein–protein interactions. Yet discovering synthetic molecular glues de novo remains a major challenge, particularly due to the need to identify compounds that both engage a target and promote cooperative ternary complex formation.
